1 September 2021 - - US-based cardiovascular diagnostic and prognostic test developer Prevencio, Inc. has presented multinational patient data demonstrating its Artificial Intelligence -driven HART CADhs blood test is more accurate than high sensitivity troponin in determining whether a patient has obstructive heart disease, the company said.

Cardiologists from University Heart Center of Hamburg Germany, Massachusetts General Hospital, and Inova Heart and Vascular Institute collaborated to test 924 patients for blood diagnosis of heart disease.

HART CADhs had 80% accuracy as compared to high sensitivity troponin's accuracy of 63%.

The data was also highlighted in a special edition of ESC Congress News entitled Computational Cardiology--New Ways That Technology Can Improve Prediction in Coronary Syndromes.

HART CADhs had previously been reported to be more accurate (86% AUC) than standard-of-care stress tests (52% AUC accuracy).

In addition to the HART CADhs blood test for heart disease and imminent risk of heart attack, Prevencio recently launched a second multiprotein blood test, HART CVE, for one-year risk of heart attack, stroke, or cardiac death. HART CADhs and HART CVE tests are currently available for patient use.

Cardiovascular disease is the leading cause of death in the US and globally. According to the American Heart Association, the US spends approximately USD 316bn annually on cardiovascular disease and stroke, or approximately 10% of the USD 3.2tn spent on total healthcare.

By 2030, more than 40% of the US adult population is projected to have cardiovascular disease.

Powered by AI, Prevencio is revolutionizing blood tests for cardiovascular disease and custom diagnostics. Employing this novel approach, the company has developed seven blood tests that significantly improve diagnosis and risk assessment for a variety of heart and blood vessel-related complications.

HART test results have been peer-reviewed published 23 times, including at leading cardiovascular meetings--(European Society of Cardiology Congress 2016, 2018, 2021; American College of Cardiology Scientific Sessions 2017, 2018, 2019 (2), 2020, 2021; American Heart Association Scientific Sessions 2017, 2018, 2019; American Diabetes Association Scientific Sessions 2018, 2019; and Pediatric Academic Societies International Sessions 2021) and in top-tier journals--(Journal of American College of Cardiology Mar 2017; American Journal of Cardiology July 2017; Clinical Cardiology June 2018; Open Heart November 2018, May 2019; Jan 2019; Biomarkers in Medicine June 2020; Journal of American Heart Association Aug 2020).

Prevencio utilizes Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers + Proprietary Algorithms to deliver cardiovascular diagnostic and prognostic tests that are significantly more accurate than standard-of-care stress tests.

The company is headquartered in Kirkland, Washington.